Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma

# Background Further research is needed to determine real-world costs of first-line (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), modified FFX (mFFX), and gemcitabine with nab-paclitaxel (GnP). # Objectives To describe healthcare costs by treatment reg...

Full description

Bibliographic Details

Published in:	Journal of Health Economics and Outcomes Research
Main Authors:	Syvart Dennen, Marty Masek, Paul Cockrum, Elizabeth Nagelhout, Ravi Paluri
Format:	Article
Language:	English
Published:	Columbia Data Analytics, LLC 2025-08-01
Online Access:	https://doi.org/10.36469/001c.142403